Claims
- 1. A method of treatment of the human or non-human animal body for treating or preventing NO-dependent microcirculation disorders or of disease states where such microcirculation disorders are involved, said method comprising administering to said body an effective amount of a pharmaceutical composition comprising a substance which scavenges free radicals.
- 2. A method according to claim 1, in which the substance scavenges free oxi- and/or peroxi-radicals.
- 3. A method according to claim 1, in which the substance acts as cellular membrane bound substance.
- 4. A method according to claim 1 in which the substance is a pyrimidino-pyrimidine selected from Dipyridamole, Mopidamol and the pharmaceutically acceptable salts thereof.
- 5. The method of claim 1, characterized in that the pyrimidopyrimidine is Dipyridamole.
- 6. A method according to claim 1 in which the substance is administered in combination with one or more agents capable to increase NO production.
- 7. The method of claim 1, characterized in that the NO dependent microcirculation disorder is selected from the group consisting of
microcirculation disorders caused by metabolic diseases where vascular damages are involved,
such as diabetic angiopathy, especially diabetic microangiopathy, e.g. diabetic gangrene, diabetic retinopathy, diabetic neuropathy, or such as hyperhomocysteinemia, homocysteinuria, pulmonary hypertension, mucoviscidosis, neuro-degenerative disease, ulcus cruris, atrophic gastritis, colitis ulcerosa, partial resection of stomach and/or bowels, insufficient tissue perfusion after revascularisation of large arteries such as after acute MI or Stroke or in peripheral artery disease in addition or following acute antiplatelet therapy to prevent acute reocclusion, conditions where dysfunction is caused by re-perfusion injury after revasularisation or in transplant recipient, microcirculation disorders caused by inflammatory reactions,
such as morbus erohn, colitis ulcerosa or acute respiratory dystress syndrome (ARDS), microcirculation disorders caused by autoimmune diseases,
such as autoimmune chronic-active hepatitis (idiopathic hepatitis), primary-biliary cirrhosis or (autoimmune associated) multiple sclerosis, peripheral microcirculation disorders,
such as Raynaud's disease, tinnitus or sudden loss of hearing, microcirculation disorders associated with increased cell fragmentation,
such as tumor diseases or thrombotic-thrombocytopenic purpura (TTP), or, as further indications, nephrosclerosis, prerenal hypertension, haemolytic-uremic syndrome (HUS), arterial hypertension, vascular dementia, Alzheimer's disease, Sudeck's disease, central-veneous thrombosis of the eye, ischemic optic neuropathy, homocystine-induced vasculopathy, ischemic or coronary heart diseases, prevention of myocardial infarction or reinfarction, treatment or prevention of atherosclerosis, degenerative diseases of joints such as arthritis.
- 8. The method of claim 4, wherein a plasma level of about 0.2 to 5 μmol/L of the pyrimido-pyrimidine is maintained.
- 9. The method of claim 4, wherein the pyrimido-pyrimidine is administered using an oral retard, instant or a parenteral formulation.
- 10. The method of claim 4, wherein the pyrimido-pyrimidine is administered orally in a daily dosage of 25 to 450 mg or parenterally in a dosage of 0.5 to 5 mg/kg body weight during 24 hours.
- 11. The method of claim 6, wherein the agent is a HMG CoA reductase inhibitors.
- 12. The method of claim 7, wherein for treatment of a microcirculation disorder associated with increased cell fragmentation a plasma level of Dipyridamole or Mopidamol of about 0.2 to 50 μmol/L is maintained.
Priority Claims (1)
Number |
Date |
Country |
Kind |
DE 101 19 680.6 |
Apr 2001 |
DE |
|
RELATED APPLICATIONS
[0001] Benefit of U.S. Provisional Application Serial No. 60/288,605, filed on May 4, 2001, is hereby claimed.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60288605 |
May 2001 |
US |